Roche’s Polivy (polatuzumab vedotin) Receives Health Canada’s Approval For R/R Diffuse Large B Cell Lymphoma

 Roche’s Polivy (polatuzumab vedotin) Receives Health Canada’s Approval For R/R Diffuse Large B Cell Lymphoma

Roche’s Polivy (polatuzumab vedotin) Receives Health Canada’s Approval For R/R Diffuse Large B Cell Lymphoma

Shots:

  • Health Canada, under (NOC/c) policy, has granted market authorization to Polivy + bendamustine and rituximab (BR) for six 21-day cycles in adult patients with r/r DLBCL, who are not eligible for ASCT and prior treated with at least one therapy
  • The approval is based on P-I/II GO29365 study assessing Polivy + BR vs BR alone in 80 patients, including 4 Canadians with previously treated DLBCL.  Results: patients achieving CR or PR (40% vs 18%); mDoR (12.6 vs 7.7mos.)
  • Polivy is an ADC, targeting CD79b and destroys the B cells through the delivery of an anti-cancer agent, while minimizing the effects on normal cells

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: The Hindu

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post